Prevalence of chronic obstructive pulmonary disease in the global population with HIV: a systematic review and meta-analysis Jean Joel Bigna, MD, Angeladine Malaha Kenne, MPH, Serra Lem Asangbeh, MPH, Aurelie T Sibetcheu, MD The Lancet Global Health Volume 6, Issue 2, Pages e193-e202 (February 2018) DOI: 10.1016/S2214-109X(17)30451-5 Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions
Figure 1 Study selection The Lancet Global Health 2018 6, e193-e202DOI: (10.1016/S2214-109X(17)30451-5) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions
Figure 2 Random-effects meta-analysis results for prevalence of COPD in the global population with HIV, by diagnostic criteria LLN=post-bronchodilator FEV1/FVC less than 5% age-dependent lower limit of normal. FEV1=post-bronchodilator forced expiratory volume in 1 s. FVC=forced vital capacity. Fixed-ratio=post-bronchodilator FEV1/FVC less than 0·70. ICD=International Classification of Diseases. The Lancet Global Health 2018 6, e193-e202DOI: (10.1016/S2214-109X(17)30451-5) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions
Figure 3 Forest plot of the association between exposure to HIV infection and COPD The Lancet Global Health 2018 6, e193-e202DOI: (10.1016/S2214-109X(17)30451-5) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions